Emsons Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.10 Cr
as on 06-12-2024
- Paid Up Capital ₹ 1.10 Cr
as on 06-12-2024
- Company Age 67 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.15 Cr
as on 06-12-2024
- Revenue 13.04%
(FY 2020)
- Profit 11.27%
(FY 2020)
- Ebitda -14.32%
(FY 2020)
- Net Worth 0.22%
(FY 2020)
- Total Assets 1.16%
(FY 2020)
About Emsons Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.10 Cr and a paid-up capital of Rs 1.10 Cr.
The company currently has active open charges totaling ₹1.15 Cr.
Gobinda Chattopadhyay and Molly Chattopadhyay serve as directors at the Company.
- CIN/LLPIN
U02005WB1957PTC023335
- Company No.
023335
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jan 1957
- Date of AGM
08 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Emsons Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gobinda Chattopadhyay  | Managing Director | 24-Nov-2004 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Molly Chattopadhyay | Director | 24-Nov-2004 | Current |
Financial Performance of Emsons Pharmaceuticals.
Emsons Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced significant growth in revenue, with a 13.04% increase. The company also saw a substantial improvement in profitability, with a 11.27% increase in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emsons Pharmaceuticals?
In 2020, Emsons Pharmaceuticals had a promoter holding of 78.07% and a public holding of 21.93%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Madhuban Commercial Pvt LtdActive 28 years 10 monthsGobinda Chattopadhyay and Molly Chattopadhyay are mutual person
- Mun Mark Export Pvt LtdActive 28 years 10 months
Gobinda Chattopadhyay and Molly Chattopadhyay are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Of Commerce Creation Date: 18 Oct 2005 | ₹8.95 M | Open |
Indian Bank Creation Date: 20 Feb 2005 | ₹2.50 M | Open |
How Many Employees Work at Emsons Pharmaceuticals?
Unlock and access historical data on people associated with Emsons Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emsons Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emsons Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
